Search
Cue Biopharma Inc
CUEAdd to Watchlist
28.260USD
-0.080-0.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.28%
5 Days
+11.30%
1 Month
+5.02%
6 Months
+179.19%
Year to Date
+208.45%
1 Year
+3965.02%
Key Figures
29.000Open
29.547High
33.40KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.04%Turnover Ratio
28.340Prev. Close
27.250Low
614.71KTurnover
LossP/E Static
165.95P/B
0.00%Div Yield TTM
-73.49%ROA
41.42052wk High
0.50Volume Ratio
-40.67MNet Profit
77.78MShares
-35.7843EPS TTM
2.52Beta
-138.52%ROE
4.97152wk Low
8.10%Amplitude
100.00%Gross Margin
2.20BMarket Cap
-0.41Reward/Risk
10.67%Risk Rate
TradingKey Stock Score of Cue Biopharma Inc
Currency: USD Updated: 2026-07-02Key Insights
Cue Biopharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 60 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 115.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cue Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Cue Biopharma Inc Highlights
StrengthsRisks
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 400.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.47M.
Overvalued
The company’s latest PE is -0.79, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.86M shares, decreasing 3.75% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.95.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
115.000
Target Price
+305.79%
Upside Space
Cue Biopharma Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cue Biopharma Inc Info
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Ticker SymbolCUE
CompanyCue Biopharma Inc
CEOAzam (Usman)
Websitehttps://www.cuebiopharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cue Biopharma Inc (CUE)?
The current price of Cue Biopharma Inc (CUE) is 28.26.
What is the symbol of Cue Biopharma Inc?
The ticker symbol of Cue Biopharma Inc is CUE.
What is the 52-week high of Cue Biopharma Inc?
The 52-week high of Cue Biopharma Inc is 41.42.
What is the 52-week low of Cue Biopharma Inc?
The 52-week low of Cue Biopharma Inc is 4.97.
What is the market capitalization of Cue Biopharma Inc?
The market capitalization of Cue Biopharma Inc is 2.20B.
Is Cue Biopharma Inc (CUE) currently rated as Buy, Hold, or Sell?
According to analysts, Cue Biopharma Inc (CUE) has an overall rating of Buy, with a price target of 115.00.
What is the Earnings Per Share (EPS TTM) of Cue Biopharma Inc (CUE)?
The Earnings Per Share (EPS TTM) of Cue Biopharma Inc (CUE) is -8.42.